Reimbursement OK'd in Japan for Abbott's Xience Sierra stent

|About: Abbott Laboratories (ABT)|By:, SA News Editor

The Japanese Ministry of Health, Labor and Welfare has granted reimbursement for Abbott's (NYSE:ABT) newest generation of its XIENCE everolimus-eluting coronary stent called Sierra. The company says Sierra features an enhanced design, a new delivery system and unique sizes to help doctors treat challenging cases.

Subscribe for full text news in your inbox